Abstract:
PURPOSE: A novel macrolide compound having an inhibiting activity for the growth of Helicobacter pylori is provided, which is not easily decomposed by gastric acid. CONSTITUTION: The macrolide compound is represented by formula (1), in which R1 is hydrogen, 4-methoxy phenoxy methyl, 2-methoxy phenoxy methyl or methoxy ethoxy methyl; R2 is hydrogen, acyl or lower alkoxy; R3 is the same or different and hydrogen or acyl; and Q and W form oxo together or independently -OR4 and hydrogen, wherein R4 is hydrogen. It has an inhibiting activity for the growth of Helicobacter pylori which causes several stomach diseases.
Abstract:
PURPOSE: Provided are novel pyridopyrimidine derivatives which inhibit phosphodiesterase IV activity and TNF production. Also, provided are preparing process thereof and a pharmaceutical composition containing the same. CONSTITUTION: The novel pyridopyrimidine derivative is represented by the formula(1), wherein R1 is C1-3 lower alkyl, C3-7 cycloalkyl, cycloalkyloxy, cycloalkyl amino, cycloalkyl lower alkyl, C1-3 lower alkoxy, formyl, hydroxy lower alkyl or carboxyalkyl; R is hydrogen, methyl, C3-7 lower alkyloxy, phenyl, benzyl, substituted phenyl(wherein a substituent group includes cyano, halogen, carboxylalkyl, nitro, methyl, trihalogenated ethyl or alkyloxy; and substitution site can be ortho-, meta-, or para- site), alkyloxy, C3-7 lower alkyloxy ethyl, benzyloxy, benzyloxyethyl, phenyloxyethyl, carboxyalkyl or cyano group; and R4 is hydrogen or methyl group, provided that R2 and R3 are not the same.
Abstract:
PURPOSE: Provided is (E)-prophenyl quaternary ammonium cephem compound and a pharmaceutically acceptable salt and a method for preparation thereof. The prepared compound has excellent antibacterial activity against both gram positive and gram negative strains, and is thus used for Cephalosporin based medicines. CONSTITUTION: (E)-prophenyl quaternary ammonium cephem compound is represented by the formula(1), wherein R1 is hydrogen, formyl, t-buthoxycarbonyl, benzyloxycarbonyl, p-nitrobenzyloxycarbonyl or trithyl; R2 is hydrogen, methyl, 2-fluoroethyl, formyl, chloroacetyl, benzoyl, p-nitrobenzyl, 2,2,2-trichloroethoxycarbonly, tetrahydropyranyl or trithyl; R3 is hydrogen, group forming carboxylic salt, 2,2,2-trichloroethyl, p-methoxybenzyl, p-nitrobenzyl, benzhydryl or t-butyl; R4 is methoxy, carbamoyl having substituent, or C5 hetero ring substituent represented by oxydiazole or triazole; and n is an integer of 1 or 2.
Abstract:
PURPOSE: A novel macrolide compound having an inhibiting activity for the growth of Helicobacter pylori is provided, which is not easily decomposed by gastric acid. CONSTITUTION: The macrolide compound is represented by formula (1), in which R1 is hydrogen, 4-methoxy phenoxy methyl, 2-methoxy phenoxy methyl or methoxy ethoxy methyl; R2 is hydrogen, acyl or lower alkoxy; R3 is the same or different and hydrogen or acyl; and Q and W form oxo together or independently -OR4 and hydrogen, wherein R4 is hydrogen. It has an inhibiting activity for the growth of Helicobacter pylori which causes several stomach diseases.
Abstract:
본 발명은 신규 박테리아 균주 KME-002 및 이의 용도에 관한 것으로, 더욱 상세하게는 멍게로부터 분리한 해양 박테리아 균주 KME-002의 유전자 형태 및 생화학적 성상을 분석하여 신규 박테리아 균주임이 밝혀졌으며, 상기 균주가 담즙의 주성분인 콜린산(cholic acid) 유도체 중 7-케토데옥시콜린산(7-ketodexoycholic acid) 및 3-옥소데옥시콜린산(3-Oxodeoxycholic acid)를 생산하고, 양식 멍게에게 일명 조그랑증 및 물렁증 등의 질병을 유발하는 원인균임이 밝혀짐으로써 신규 균주 KME-002, 이의 유전체 및 성분은 콜린산 유도체의 대량생산, 및 멍게 질병 예방 및 치료에 유용하게 이용될 수 있다. 박테리아 균주 KME-002, 콜린산 유도체, 7-케토데옥시콜린산, 3-옥소데옥시콜린산, 멍제 질병.
Abstract:
PURPOSE: A novel bacteria strain Aeromicrobium halocynthiae KME-001 is provided to produce taurocholic acid amoun cholic acid derivatives and to cause disease of sea squirt. CONSTITUTION: A novel bacteria strain Aeromicrobium halocynthiae KME-001(deposit number KFCC11430P) contains 16S rDNA of sequence number 1. The novel strain is aerobic gram-positive nonsporeforming Bacillus. The strain produces taurocholic acid of chemical formula 1. A method for producing taurocholic acid comprises: a step of inoculating Aeromicrobium halocynthiae KME-001 KME-001 to liquid medium and culturing; a step of adding adsorbent resin and organic solvent or directly adding organic solvent to the culture medium; a step of performing column chromatography to obtain a fraction; a step of performing column chromatography from the fraction to obtain taurocholic acid of chemical formula 1; and a step of purifying tauroholic acid.
Abstract:
본 발명은 캡슐형 로봇 시스템에 관한 것으로서, 보다 상세하게는 인체의 소화기에 삽입되는 캡슐형 로봇 시스템에 관한 것으로서, 인체의 내장을 진단 및/또는 치료하기 위한 캡슐형 로봇 시스템에 있어서, 치료 및/또는 진단 도구가 탑재되는 본체와; 상기 본체에 설치되어 인체의 외부에서의 자기장의 변화에 의하여 상기 본체의 이동을 제어하는 외력반응부를 포함하는 것을 특징으로 한다. 캡슐형, 자석, 내시경
Abstract:
PURPOSE: A pyrazolopyridine substituted cephalosporin compound is provided, which have the wide antimicrobial activity for gram positive and gram negative bacteria. And a producing method thereof is also provided. CONSTITUTION: The pyrazolopyridine substituted cephalosporin compound is represented by formula (1), in which R1 is hydrogen, C1 to C3 alkyl, C1 to C3 alkyl containing hydroxy, C1 to C3 alkyl containing amine; and R2 is hydrogen, amino, amino protected by amine protecting groups, carboxy or its inorganic salts, carbarmoyl, C1 to C3 alkyl substituted carbarmoyl, C1 to C3 alkyl containing hydroxy, and C1 to C3 alkyl esterified carboxy. The method for producing the pyrazolopyridine substituted cephalosporin compounds comprises the steps of: reacting the compounds of formula (2) and (3); and deprotecting R3 and R4, in which R3 is amine protecting groups, R4 is carboxylic acid protecting groups; and Y is halogen or acetoxy.